siRNA Compositions Targeting CD33 Gene for Neuroinflammatory Disease Treatment
Summary
The USPTO published patent application US20260098269A1 covering single- or double-stranded interfering RNA (siRNA) molecules targeting the Siglec-5 (CD33) gene, pharmaceutical compositions containing these molecules, and methods for treating neuroinflammatory diseases including Alzheimer's disease. The application claims specific nucleoside modifications, internucleoside linkage modifications, branched siRNA configurations (di-branched, tri-branched, tetra-branched), 5′ phosphorus stabilizing moieties, hydrophobic moieties, and CNS delivery methods.
What changed
The USPTO published patent application US20260098269A1 for compositions and methods treating neuroinflammatory diseases by targeting the CD33 (Siglec-5) gene using modified siRNA molecules. The application claims novel siRNA structures including branched configurations (di-branched, tri-branched, tetra-branched), specific nucleoside and internucleoside linkage modifications, 5′ phosphorus stabilizing moieties, and hydrophobic modifications. Methods for delivering these molecules to the central nervous system of subjects with neuroinflammatory conditions are also claimed.
For biotechnology and pharmaceutical companies developing RNA-based therapeutics, this patent application represents potential prior art for CD33-targeting programs and may affect freedom-to-operate considerations for neuroinflammatory disease treatments. The claimed modifications and delivery methods could inform competitor research strategies or necessitate licensing discussions upon patent grant.
What to do next
- Monitor for patent grant or office action
- Review claims for freedom-to-operate analysis
- Assess competitive landscape for CD33-targeting therapeutics
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROINFLAMMATORY DISEASES
Application US20260098269A1 Kind: A1 Apr 09, 2026
Inventors
Corrie GALLANT-BEHM, Wimalanathan KOKULAPALAN, Benjamin ANDREONE, Matthew HASSLER, Daniel CURTIS, Bruno Miguel DA CRUZ GODINHO
Abstract
The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and/or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).
CPC Classifications
C12N 15/1138 C12N 2310/14 C12N 2310/315 C12N 2310/321 C12N 2310/3341
Filing Date
2023-09-28
Application No.
19115529
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.